Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Link
http://link.springer.com/article/10.1007/s40259-018-0315-0/fulltext.html
Reference75 articles.
1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2012;19(1):e1–47.
2. Iorio A, Krishnan S, Myrén K-J, Lethagen S, McCormick N, Yermakov S, et al. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. J Med Econ. 2017;20(4):337–44.
3. Ljung R, Fischer K, Carcao M, Santagostino E, Manco-Johnson MJ, Mathew P, et al. Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thromb Haemost. 2016;115(5):913–20.
4. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014;20(Suppl 4):99–105.
5. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus. 2012;10(2):165–8.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Laboratory response to paradigm change in hemophilia treatment;Clinical Chemistry and Laboratory Medicine (CCLM);2023-06-15
2. Emicizumab for acquired haemophilia A: A case series;Haemophilia;2023-06-05
3. FVIII at the crossroad of coagulation, bone and immune biology: Emerging evidence of biological activities beyond hemostasis;Drug Discovery Today;2022-01
4. Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021;Blood Reviews;2021-11
5. An update of the current pharmacotherapeutic armamentarium for hemophilia A;Expert Opinion on Pharmacotherapy;2021-08-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3